ReviewCureus2026
The Potential Therapeutic Effects of Testosterone on Sarcopenia: A Thorough Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is characterized by a progressive loss of skeletal muscle mass and function with aging, often resulting in functional decline and reduced independence. Although it primarily affects older adults, its development is multifactorial and may be influenced by various underlying factors. Testosterone, the primary endogenous male androgen, promotes skeletal muscle protein synthesis by activating pathways involved in muscle growth, cellular energy, and tissue repair. As testosterone levels decline with age, decreases in muscle strength and increases in frailty may occur, prompting investigation into testosterone replacement therapy (TRT) as a potential therapeutic intervention. This systematic review examines evidence from 15 studies comparing the effects of testosterone in patients with sarcopenia, with a focus on efficacy and functional improvements. Key outcomes include changes in lean body mass, strength performance, and physical function indicators. Our findings suggest that TRT can increase lean muscle mass and strength to a lesser extent, but improvements in mobility or daily function are inconsistent among population groups. Evidence regarding long-term safety and efficacy, as well as responses in the presence of other comorbidities, is limited. Current best practice recommendations emphasize exercise and a protein-rich diet as the primary approach for sarcopenia. This review aims to clarify the therapeutic role of testosterone in managing sarcopenia, highlight current limitations in the evidence base, and identify critical directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.